CBMG takes ride on CAR data

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) gained $4.51 (14%) to $35.64 on news its chimeric antigen receptor (CAR) T cell therapy targeting CD30 led to partial responses in two of seven patients in a Phase I study to treat progressive relapsed/refractory Hodgkin's lymphoma. Three additional patients had stable disease after receiving the therapy, which consists of T cells expressing a CAR specific to the CD30 antigen.

One patient had an adverse event: five-day self-limiting arthralgias, myalgias and dual knee swelling two weeks after cell infusion. ...